Cargando…

Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment

INTRODUCTION: Activation of the phosphatidylinositol-3-kinase (PI3K) and/or mitogen-activated protein kinase (MAPK) pathways results in anti-estrogen resistance in vitro, but a biomarker with clinical validity to predict intrinsic resistance has not been identified. In metastatic breast cancer patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beelen, Karin, Opdam, Mark, Severson, Tesa M, Koornstra, Rutger HT, Vincent, Andrew D, Wesseling, Jelle, Muris, Jettie J, Berns, Els MJJ, Vermorken, Jan B, van Diest, Paul J, Linn, Sabine C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979131/ https://www.ncbi.nlm.nih.gov/pubmed/24447434 http://dx.doi.org/10.1186/bcr3598

Ejemplares similares

PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients
por: Beelen, Karin, et al.
Publicado: (2014)

Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot
por: Beelen, Karin, et al.
Publicado: (2018)

CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
por: Beelen, K., et al.
Publicado: (2013)

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation
por: Severson, Tesa M., et al.
Publicado: (2016)

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites
por: Jager, Nynke GL, et al.
Publicado: (2013)

IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women
por: Joosten, Stacey E. P., et al.
Publicado: (2021)

Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13
por: Bentin Toaldo, Cristiane, et al.
Publicado: (2015)

Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients
por: Dackus, Gwen M H E, et al.
Publicado: (2021)

PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy
por: Beelen, Karin, et al.
Publicado: (2014)

Adjuvant tamoxifen for early breast cancer.
por: Smith, I.
Publicado: (1988)

Tamoxifen resistance and adjuvant hormone therapy
por: Howell, A
Publicado: (2005)

Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
por: van Nes, J. G. H., et al.
Publicado: (2012)

Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment
por: Michalides, R, et al.
Publicado: (2002)

Adjuvant tamoxifen for male breast cancer (MBC).
por: Ribeiro, G., et al.
Publicado: (1992)

Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer
por: Aydiner, Adnan, et al.
Publicado: (2008)

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
por: Gjerde, Jennifer, et al.
Publicado: (2010)

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial
por: Trialists' Group, The ATAC
Publicado: (2001)

Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids
por: Francini, G, et al.
Publicado: (2006)

Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen
por: Jansen, Maurice P.H.M., et al.
Publicado: (2016)

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
por: Wegman, Pia, et al.
Publicado: (2005)

Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
por: Dowsett, M., et al.
Publicado: (1984)

AGR2 Predicts Tamoxifen Resistance in Postmenopausal Breast Cancer Patients
por: Hrstka, Roman, et al.
Publicado: (2013)

Polypoid endometriosis mimicking invasive cancer in an obese, postmenopausal tamoxifen user
por: Jaegle, William T., et al.
Publicado: (2017)

Effects of tamoxifen and exemestane on cognitive function in postmenopausal patients with breast cancer
por: Lee Meeuw Kjoe, Philippe R, et al.
Publicado: (2023)

IARC on tamoxifen.
Publicado: (1996)

Tamoxifen evolution
por: Howell, A., et al.
Publicado: (2023)

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
por: Loi, Sherene, et al.
Publicado: (2008)

The Christie hospital adjuvant tamoxifen trial--status at 10 years.
por: Ribeiro, G., et al.
Publicado: (1988)

Adherence to Adjuvant Tamoxifen in Mexican Young Women with Breast Cancer
por: Martinez-Cannon, Bertha Alejandra, et al.
Publicado: (2021)

Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors
por: Uslu, Yasemin, et al.
Publicado: (2023)

A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples
por: Zwart, Wilbert, et al.
Publicado: (2013)

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)—PathIES
por: Szijgyarto, Zsolt, et al.
Publicado: (2019)

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2015)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
por: Wang, Yuntao, et al.
Publicado: (2021)

Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women
por: Marttunen, M B, et al.
Publicado: (2001)

Comparative Study on Hysteroscopic and Histologic Examinations of the Endometrium in Postmenopausal Women Taking Tamoxifen
por: Jung, Hyuk, et al.
Publicado: (2018)

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk
por: van ‘t Veer, Laura J., et al.
Publicado: (2017)

Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis
por: Al-Mubarak, Mustafa, et al.
Publicado: (2014)

Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk
por: Pistilli, Barbara, et al.
Publicado: (2020)

Tamoxifen and the Singing Voice
por: Herxheimer, Andrew
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_2optahjcbe1ktpjcefb5f3u0a6